These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 11686022)
1. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. Huang SM; Li J; Harari PM Cancer Chemother Biol Response Modif; 2001; 19():339-52. PubMed ID: 11686022 [No Abstract] [Full Text] [Related]
2. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Mendelsohn J Clin Cancer Res; 2000 Mar; 6(3):747-53. PubMed ID: 10741693 [No Abstract] [Full Text] [Related]
3. EGF receptors as a target for cancer therapy. Mendelsohn J Trans Am Clin Climatol Assoc; 2004; 115():249-53; discussion 253-4. PubMed ID: 17060971 [No Abstract] [Full Text] [Related]
4. Epidermal growth factor receptor: a promising target in solid tumours. Laskin JJ; Sandler AB Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123 [TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Boland WK; Bebb G Expert Opin Biol Ther; 2009 Sep; 9(9):1199-206. PubMed ID: 19624281 [TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Ho DT; Wykoff-Clary S; Gross CS; Schneider D; Jin F; Kretschmer PJ; Hermiston TW Cancer Gene Ther; 2009 Feb; 16(2):184-94. PubMed ID: 18758433 [TBL] [Abstract][Full Text] [Related]
7. Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice. Baradaran B; Hosseini AZ; Majidi J; Farajnia S; Barar J; Saraf ZH; Abdolalizadeh J; Omidi Y Hum Antibodies; 2009; 18(1-2):11-6. PubMed ID: 19478394 [TBL] [Abstract][Full Text] [Related]
8. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Tortora G; Ciardiello F; Gasparini G Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and targeting of colorectal cancer. Vanhoefer U Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005 [TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor as a target for therapy. Harris AL Cancer Cells; 1990 Oct; 2(10):321-3. PubMed ID: 2282249 [No Abstract] [Full Text] [Related]
18. Jeremiah Metzger Lecture. Targeted cancer therapy. Mendelsohn J Trans Am Clin Climatol Assoc; 2000; 111():95-110; discussion 110-1. PubMed ID: 10881335 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? Dancey JE J Clin Oncol; 2004 Aug; 22(15):2975-7. PubMed ID: 15210735 [No Abstract] [Full Text] [Related]